EoCene Ltd. EOCN
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
EoCene Ltd. (EOCN) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
About EoCene
EoCene is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 0 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $2M | $1M | $467000 |
| Net income | -$10M | -$8M | -$7M | -$18M | -$32M | -$29M | -$20M | -$10M | -$12M | -$17M |
| Free cash flow | — | — | — | -$19M | -$33M | -$26M | -$15M | -$9M | -$12M | -$12M |
| EPS (diluted) | $-9.90 | $-7.22 | $-6.64 | $-17.15 | $-31.17 | $-27.62 | $-19.64 | $-9.46 | $-11.81 | $-16.28 |
| Net margin | — | — | — | — | — | — | — | -483.6% | -1133.5% | -3630.2% |
| ROIC | — | — | — | — | — | -67.8% | -31.8% | -9.6% | -78.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does EoCene pay a dividend?
Not currently.
Is EoCene a good stock to buy?
We do not give buy or sell advice. EoCene scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.